US pharma giant Merck & Co (NYSE: MRK) has presented positive results from two pivotal Phase III trials of the ...

Interim data on Spineart’s Baguera-C cervical disc shows the device meets the threshold for a non-inferiority claim compared to a study control, the medtech company said March 11. Spineart plans to ...

According to Abbey, the trial achieved its primary endpoint of noninferiority in change in best corrected visual acuity with EYP-1901 (vorolanib intravitreal insert, EyePoint Pharmaceuticals ...

Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiorityGeneva, March 11, 2025 – Spineart, a fast-growing company in ...

Treatment with thermal ablation was noninferior to surgical resection in small-size colorectal liver metastases, according to ...

This article Medtronic Announced Evolut Tavr Platform Met Both Co-primary Endpoints Of Clinical Non-inferiority And Hemodynamic Superiority At One Year originally appeared on Benzinga.com.

The minimum dose requirements for seroconversion remain unknown. In this double-blind, randomized, noninferiority trial in Uganda and Kenya, we assigned adults with no history of yellow fever ...

met the threshold for a non-inferiority claim against the study control. Spineart has now agreed on a timeline with the U.S. FDA for the submission of Premarket Approval (PMA) for BAGUERA® C in ...